Stent News: Breaking Stent News, Comments and Articles.

InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group

PARIS, May 23, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation...

Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013

SAN DIEGO and PARIS, May 23, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced preliminary results from the ADVISE (Adenosine Vasodilator Independent Stenosis Evaluation) II trial during the hot line late bre...

Computational Model Evaluates A New Way To Open Clogged Arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments has drawbacks, including the risk of side effe...

Further Data on STENTYS Self-Apposing Stent Reinforces Strength of Clinical Results

New Sub-group Analysis of APPOSITION III Presented at EuroPCR in Paris STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today new one-year data from the APPOSITI

Direct Flow Medical Transcatheter Aortic Valve System Demonstrates Excellent 30 Day Outcomes Following Full Enrollment of DISCOVER CE Mark Trial

Results Presented in Oral Presentation at EuroPCR Direct Flow Medical®, Inc., a transcatheter heart valve company focused on improving patient outcomes, today announced that it has met its primary endpoint in the fully-enrolled, 100-patient DISCOVER CE Mark Trial by achieving 99 percent freedom from all-cause mortality at 30 days. Patients were...

Boston Scientific Promus PREMIER™ And SYNERGY™ Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data

PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease.  Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER™ Everolimus-Elut...

For Bifurcation Lesions in Coronary Arteries, Medtronic's Resolute Stent Delivers Strong Long-Term Results

Three Analyses Presented at EuroPCR Demonstrate Device's Durability in Addressing Common Clinical Challenge PARIS -- May 22, 2013 -- Addressing one of the most common clinical challenges in the treatment of complex coronary artery disease, three separate analyses on the program for EuroPCR this week show how strongly the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) performs...

Study analyzes potential usefulness of new treatment to reopen clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents.

Drug-coated Balloons May Provide New Method To Open Clogged Arteries

A new treatment method that combines the advantages of angioplasty balloons and drug-releasing stents, and offers fewer risks, has been examined as a way to open clogged arteries. The study, led my MIT researchers and published in the journal Circula...

Biodegradable stent proves non-inferior to drug-eluting stent

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine mont...

Elixir Medical Announces Excellent Six-Month Safety and Efficacy Results for the CE-Marked Fully Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System at Late Breaking Clinical Trial Session of EuroPCR

Data show an increase in the scaffold and lumen area, re-establishing the vessel’s natural ability to positively remodel at 6 months Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced excellent six-month clinical trial results today from the DESolve Nx in...

Fourth Quarter Caps Solid Year for Medtronic

Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported Q4 Non-GAAP Diluted EPS Growth of 11%; GAAP Diluted EPS Growth of 1% Q4 International Revenue Grew 7% at Constant Currency; 4% as Reported FY13 Revenue of $16.6 Billion Grew 5% at Constant Currency; 3% as Reported FY13 Free Cash Flow of $4.4 Billion; GAAP Cash Flow from Operations of $4.9 Billion

Abbott announces CE Mark for world’s longest coronary drug eluting stent

Abbott announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System...

Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent

ABBOTT PARK, Ill., May 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the proven design and clinical outcomes of the...

Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets

MOUNTAIN VIEW, Calif., May 21, 2013 /PRNewswire/ -- Healthcare organizations expanding into emerging markets like Brazil, Russia, India and China (BRIC) are realizing there are no shortcuts.  This is proving particularly challenging, considering the current healthcare environment, especially in the United States.  Companies must change the dialogue around BRIC, as it is now more abo...

Evaluating a new way to open clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments has drawbacks, including the risk of side effe...

Cordis Showcases Cardiovascular Innovations at EuroPCR 2013

Cordis Corporation, a global leader in innovative technology for cardiovascular interventions, will introduce the two latest additions to its portfolio of cardiovascular solutions at EuroPCR 2013, 21-24 May in Paris. EuroPCR is Europe’s largest meeting for interventional cardiovascular medicine. “We are excited to meet with our physician colle...

OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings

WIESBADEN, Germany, May 21, 2013 /PRNewswire/ -- Medical device manufacturer OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively "OrbusNeich") today announced that it has enforced the seizure of over 190 stent systems from Boston Scientific Corporation (NYSE: BSX) in connection with its patent infringement proceedings in the Dusseldorf Regional Court. The product...

Verrata™ Pressure Guide Wire and iFR® (Instant Wave-Free Ratio™) Software Modality will be on display at EuroPCR 2013[1]

SAN DIEGO, May 21, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will demonstrate the Verrata™ Pressure Guide Wire and the iFR® (Instant wave-Free Ratio™) modality throughout the w...

Delayed Healing of Coronary Artery Following Implantation of Drug Eluting Stents, Increasing Risk of Thrombosis, is a Top Concern of Interventional Cardiologists, International Survey Shows

PARIS, May 21, 2013 /PRNewswire/ -- The delayed healing of the coronary artery following physicians' use of drug eluting stents (DES), which increases patients' risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris. In the online survey of 141 interventional cardiologists in Belgium, Chi...

Medtronic to Honor Those Who Give Back After Receiving Life-Enhancing Medical Technology

(View the Bakken Invitation video here) Live On. Give On:  Ten inspirational people will be awarded a $20,000 charitable donation and be honored at an awards celebration in Hawaii as part of the first annual Bakken Invitation MINNEAPOLIS - May 20, 2013- Medtronic, Inc. (NYSE: MDT) announced today that applications are being accepted for the inaugural Bakken Invitation, a global program desig...

STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial

STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that the first patient was enrolled in APPOSITION V, the pivotal FDA-approved IDE trial which will enable the Company to apply for marketing approval of the Self...

Vention Medical Launches Online Tool to Speed R&D

ModCathTM to provide modular balloon catheter prototypes in as little as two weeks Vention Medical announced today the launch of an online tool that allows customers to design their own balloon catheter prototypes built to their specifications, for delivery in as little as two weeks. The new ModCathTM Online Design Tool allows users to select...

Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device

Allegheny General Hospital (AGH) in Pittsburgh has been selected to join the ABSORB III clinical trial, a multi-center international study exploring a unique bioresorbable vascular scaffold (BVS), a small mesh tube that is designed to open a blocked artery and then fully dissolve over time, leaving the vessel free of a permanent metallic implant. The FDA-approved study of the drug-eluting Absorb...

OrbusNeich's Genous™ Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients

HONG KONG, May 20, 2013 /PRNewswire/ -- OrbusNeich today announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an investigator-initiated randomized study, were published in the Ju...